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Summary 
The International Federation of Pigment Cell 
Societies (IFPCS) held its XXIII triennial International 
Pigment Cell Conference (IPCC) in Denver, Colorado in 
August 2017. The goal of the summit was to provide a venue 
promoting a vibrant interchange among leading basic and 
clinical researchers working on leading-edge aspects of 
melanocyte biology and disease. The philosophy of the 
meeting, entitled Breakthroughs in Pigment Cell and 
Melanoma Research, was to deliver a comprehensive 
program in an inclusive environment fostering scientific 
exchange and building new academic bridges. 
Significance 
This document provides an outlook on the 
history, accomplishments, and sustainability of the pigment 
cell and melanoma research community. Shared progress in 
the understanding of cellular homeostasis of pigment cells 
but also clinical successes and hurdles in the treatment of 
melanoma and dermatological disorders continue to drive 
future research activities. A sustainable direction of the 
societies creates an international forum identifying key 
areas of imminent needs in laboratory research and clinical 
care and ensures the future of this vibrant, diverse and 
unique research community at the same time. 
Important advances showcase wealth and 
breadth of the field in melanocyte and melanoma research 
and include emerging frontiers in melanoma 
immunotherapy, medical and surgical oncology, 
dermatology, vitiligo, albinism, genomics and systems 
biology, precision bench-to-bedside approaches, 
epidemiology, pigment biophysics and chemistry, and 
evolution. This report recapitulates highlights of the 
federate meeting agenda designed to advance clinical and 
basic research frontiers from melanoma and 
dermatological sciences followed by a historical perspective 
of the associated societies and conferences. 
Introduction—Program highlights of the XXIII 
IPCC 
The XXIII IPCC encompassed a series of opening 
and award lectures, including the IFPCS Presidential lecture 
and honorary lectures by the recipients of the Fitzpatrick, 
Lerner, and Seiji Awards. These awards are bestowed by 
regional pigment cell societies to leading international 
scientists who have made extraordinary contributions to 
pigment cell research. There were 8 plenary sessions and 32 
concurrent sessions accomplishing a balance between 
clinical and basic melanoma and dermatology research. 
In addition to opening lectures, the first day 
included a plenary session on the evolution of pigmentary 
systems across the animal kingdom and three concurrent 
sessions on advances in vitiligo, melanocyte, and melanoma 
biology as well as disease management. On the second day, 
two plenary sessions covered fascinating advances in the 
genetics of coloration in various animal species and in UV 
light responses and DNA repair. The fourth day included 
two plenary sessions and four concurrent sessions that 
emphasized basic biology of melanoma and the latest 
developments in translational melanoma therapies and 
resistance. Day five was headlined by a plenary session with 
keynote speakers on the impact of regenerative medicine 
on pigmentary diseases and a plenary session on the 
immunologic control of melanocytes and melanoma. 
General sessions covered evolutionary biology of 
pigmentation, developmental biology, genetics, genomic 
profiling, neuroscience and pigmentation, melanocyte stem 
cells and regenerative medicine, hair biology, mouse and 
non-mouse models of pigmentation, melanosome 
biogenesis and transfer, melanin function and chemistry, 
and UV signaling in the melanocyte. The program also 
included three lunchtime poster sessions with presentation 
of about 200 posters. Importantly, sessions were 
specifically dedicated to provide mentoring and career 
opportunities for young scientists, women in science, and 
underrepresented minorities in science. 
The basic and clinical melanoma research 
sessions presented a state-of-the-art picture of 
immunotherapy, precision medicine, and genomic profiling 
of skin cutaneous, uveal, mucosal, and acral melanoma [1]. 
Keynote speaker Dr. Jeffrey Weber highlighted progress in 
melanoma management, while keynote speaker Dr. 
Douglas Brash presented the latest developments in DNA 
damage and melanoma risk with his work on UV-induced 
DNA damage and chemiexcitation of melanin. Frontiers of 
basic melanoma biology were introduced by keynote 
speaker Dr. Richard Marais who presented advances in 
targeted melanoma research integrating mouse models 
and therapies. The basic and clinical dermatology research 
sessions covered pigmentary processes, diseases, and 
treatments. The program featured keynote speakers 
including Dr. Sarah Tishkoff who addressed the genetic 
basis for skin pigmentation in African populations [2, 3]. Dr. 
Hopi Hoekstra identified the molecular basis of parental 
care evolution and mammalian striping phenotypes 
uncovered using the mouse as a model [4]. Dr. Rudolf 
Jaenisch provided insights into the forefront of mammalian 
embryonic and induced pluripotent stem cell research 
demonstrating the fundamental rules of cellular 
reprogramming [5]. Dr. Dennis Roop discussed progress on 
differentiating human induced pluripotent stem cells into 
keratinocytes, fibroblasts, and applications for skin grafting 
including melanocytes [6]. 
Highlights included updates on precision 
dermatology, bench-to-bedside approaches, genome-wide 
association studies, genetic diversity of pigmentation, and 
progress in immunotherapy [7]. Dr. Ian Jackson presented 
the analysis of the UK Biobank cohort of over 0.5 million 
genotyped individuals including detailed phenotype self-
reports on pigmentation and hair color. This analysis 
allowed construction of detailed polygenetic models for 
blonde and red hair color, and penetrance assessment of 
many of the low frequency melanocortin 1 receptor (MC1R) 
variants. Dr. Nicolas Hayward delivered analysis of whole-
genome sequences from cutaneous, acral and mucosal 
subtypes of melanoma. In contrast to frequently occurring 
coding and non-coding mutations in cutaneous melanoma, 
the Australian consortium resolved structural changes and 
novel signatures of mutagenesis in acral and mucosal 
melanomas, not previously identified in melanoma [8]. 
A number of presentations also explored the 
genetic diversity of pigmentation in non-human and non-
mouse systems. Dr. Cheng-Ming Chuong presented a novel 
foray into the world of feather pigment pattern formation, 
where color patterns important for animal behavior and 
speciation is modulated by the presence, arrangement, or 
differentiation of melanocytes [9]. Among many other 
important clinical advances that were introduced during 
the meeting, Dr. Robert Andtbacka presented final results 
of a phase II multicenter combination trial that included 
ipilimumab and oncolytic virus immunotherapy [10]. Teams 
of Dr. Frank Meyskens and Dr. Stephane Rocchi elucidated 
the pivotal role of metabolic and transcriptional 
reprogramming in the switch of melanoma cells toward an 
invasive and drug-resistant phenotype [11, 12]. Dr. Jeffrey 
Weber and Dr. Dirk Schadendorf pointed to the importance 
of cancer-germline antigens that predict resistance to 
therapy response [13]. 
Historical perspective of IFPCS and PASPCR 
unfolding the purpose of the IPCC—mission, vision, and 
future needs 
The International Pigment Cell Conference has 
emerged as the sole international scientific convention 
devoted to the study of the normal pigment cell and the 
advancement of basic, translational, and clinical research 
on diseases involving pigment cells. The first meeting was 
held in New York in 1946 and reconvenes on a triennial 
basis (Figure 1). Recent sites for this important international 
gathering have been Singapore (2014), Bordeaux (2011), 
and Sapporo (2008) (Table 1). While each meeting has had 
its own unique focus, commonalities for over 70 years have 
always been melanin, pigment cells and melanoma. 
In 1977, the International Federation of Pigment 
Cell Societies (IFPCS) was developed first as the 
International Pigment Cell Society and then formalized as 
IFPCS in 1990. With the IFPCS formally acting as a means to 
provide interaction between the independently formed 
sister societies, the IPCC meeting was chartered as a main 
function of IFPCS. The Japanese Society for Pigment Cell 
Research (JSPCR) was founded in 1984, the European 
Society for Pigment Cell Research (ESPCR) in 1985, the Pan-
American Society for Pigment Cell Research (PASPCR) in 
1988, and the Asian Society for Pigment Cell Research 
(ASPCR) in 2004, each becoming members of IFPCS at that 
time. Thus, the mission of the IFPCS is to disseminate 
cutting edge research via the publication of the federation’s 
journal, Pigment Cell and Melanoma Research, and to host 
the IPCC meeting. The IPCC remains the primary vehicle to 
promote worldwide scientific interchange for those 
international investigators who use an array of approaches 
to study pigment cell function in normal biology and 
disease. An international forum to present data, to discuss 
ideas, to identify key areas of needed research and to set 
new research directions is essential to ensuring the future 
of this vibrant, diverse and unique research community. 
The success of the IPCC to play this role in the pigment cell 
community is evidenced by the fact that attendance has 
been on the rise (Figure 2). 
Recapitulation of the XXIII IPCC 
The XXIII IPCC, representing the four member 
Pigment Cell Societies of the International Federation, was 
hosted by the Pan-American Society for Pigment Cell 
Research in Denver, Colorado, on August 26-30, 2017. 540 
registrants from 28 countries participated in the 8 plenary 
and 32 concurrent sessions. 8 keynote speakers led the 
program, along with 21 plenary session speakers and 80 
invited speakers. A further 103 speakers were chosen from 
submitted abstracts. The main program was complemented 
by four pre-conference satellite symposia and four 
pharmaceutical company sponsored symposia. The annual 
meeting of the Melanoma Prevention Working Group 
(MPWG) was hosted for the first time at the IPCC meeting. 
The MPWG functions under the umbrella of the Southwest 
Oncology Group (SWOG) and the Eastern Cooperative 
Oncology Group (ECOG). The MPWG meeting promoted 
clinically relevant research focused on key aspects of 
melanoma prevention and discussed innovative paths 
forward into clinical trials of chemoprevention agents for 
high-risk melanoma patients [14]. The comprehensive 
scientific program of the IPCC 2017 contained an equal 
weight of basic and clinical research in pigmentary diseases 
and melanoma. The importance of studying pigment cells is 
defined most dramatically by recent advances in melanoma 
therapies that can be lifesaving, but also by the many 
diseases and conditions intersecting with the pigmentary 
system that remain in need of effective treatments. 
A major program highlight was a dedicated 
session on advances in basic and clinical research on 
albinism. Albinism is a rare genetically inherited condition 
affecting approximately one in twenty thousand people in 
most world populations. Albinism occurs at relatively high 
frequency in sub-Saharan Africa. People with albinism 
experience visual deficits, hypopigmentation, and sun-
sensitivity. In less advanced societies, people with albinism 
may not have access to healthcare specialists, sunscreen, or 
protective clothes. Moreover, in sub-Saharan Africa, a 
humanitarian crisis is presently underway affecting patients 
with this disease [15]. The dedicated session on albinism 
raised awareness to this important issue, and sent a 
message of solidarity to patients suffering from albinism, 
leaving a unique footprint in the field of pigment cell 
biology. 
Planning and Organization of IPCC 2017—Special 
format, challenges, sustainability 
IPCC 2017 was planned for late summer, August 
26-30, 2017 in downtown Denver, Colorado. The strategy 
for designing and marketing of IPCC 2017 was informed by 
multiple lines of reasoning. First, with new melanoma 
therapies providing improvements in medical care, the field 
has progressed in an increasingly clinical direction, in some 
ways diminishing the focus on the basic research that has 
given rise to successful treatment strategies. Inevitably, 
new strategies will be needed to further advance the 
treatment of melanoma patients, and without a strong 
basic research base, these advances will not be possible. 
Moreover, successes in the translational arena of 
melanoma need to be duplicated in other key areas of 
pigment cell research, including vitiligo, melasma, and 
other pigmentary diseases. Providing a strong conference 
venue to support basic research in pigmentary diseases and 
melanoma in essence embraced the true mission of the 
IPCC meeting and of the IFPCS organization. A second 
influencing factor in designing IPCC 2017 was the 
recognition that with the World Melanoma Congress 
(WMC) associated with the Society for Melanoma Research 
(SMR) being scheduled for Brisbane in October, the IPCC 
would be the only major melanoma meeting to be held in 
the Northern Hemisphere in 2017. Thus a strong focus on 
melanoma would allow North American clinicians and 
researchers proximal access to the latest advances in the 
field. The third factor embraces all who are interested in 
pigment cell biology and disease by providing a 
comprehensive format for promoting interchange between 
such diverse groups of researchers. Thus, the theme of IPCC 
2017 was strategically chosen as Breakthroughs in Pigment 
Cell and Melanoma Research. In essence, IPCC 2017 was at 
once an outreach to all members of the community and a 
call to stand unified in facing potential funding challenges 
as a field. 
Initially, a dual focus on pigmentary disease and 
melanoma seemed to allow maximal opportunity for 
industry based meeting support. With strong support from 
the melanoma committee, major pharmaceutical company 
support was obtained to support the melanoma program. 
However, it proved more challenging to raise support from 
companies with an interest in pigment cell function and 
disease. This was compensated for by outstanding 
institutional support from groups within the University of 
Colorado system affiliated with the local organizing 
committee. Consequently, the meeting was supported by 
the melanoma related pharmaceutical industry, the 
University of Colorado, by conference registration fees and 
even through generous support from speakers, session 
chairs and attendees. 
Conclusions and Outlook 
IFPCS and the IPCC as its global forum 
The IFPCS is a vital global umbrella organization 
for the regional pigment cell societies. Over more than 
seven decades, the triennial IPCC has been an opportunity 
for scientist across the globe to gather to discuss recent 
findings, progress, and ongoing research. Consistently, the 
federation and local societies have provided the 
international research community with essential resources 
on all aspects of pigment cells including development, cell 
and molecular biology, genetics, diseases of pigment cells 
including melanoma.Declarations 
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